<DOC>
	<DOCNO>NCT00589550</DOCNO>
	<brief_summary>RATIONALE : PEG-interferon alfa-2b may interfere growth tumor cell . Sorafenib may stop growth tumor cell block enzymes need cell growth . It may also stop growth kidney cancer block blood flow tumor . Giving PEG-interferon alfa-2b together sorafenib may kill tumor cell . PURPOSE : This phase I trial study side effect best dose PEG-interferon alfa-2b sorafenib treat patient unresectable metastatic kidney cancer .</brief_summary>
	<brief_title>PEG-Interferon Alfa-2b Sorafenib Treating Patients With Unresectable Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose toxicity PEG-interferon alfa-2b sorafenib tosylate patient unresectable metastatic clear cell renal cell carcinoma . Secondary - To determine progression-free survival patient treat regimen . - To evaluate , preliminary manner , response rate overall survival patient treat regimen . - To evaluate activation interferon-induced transcription factor immune cell subset ( include regulatory T cell [ T regs ] ) use novel flow cytometric assay correlate information clinical outcome . - To measure circulate level IFN-γ IL-5 determination Th1/Th2 status CD4+ , CD25+ , FoxP3 cell number ( T regs ) peripheral blood . OUTLINE : Patients receive PEG-interferon alfa-2b subcutaneously day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 . Patients also receive oral sorafenib tosylate 2-3 time daily day 15-56 course 1 day 1-56 subsequent course . Courses repeat every 56 day 1 year absence disease progression unacceptable toxicity . Blood sample collect baseline periodically study correlative laboratory study . Peripheral blood mononuclear cell analyze STAT protein ( STAT1 , STAT2 , STAT3 , STAT4 , STAT5 ) CD4+ , CD25+ , FoxP3 regulatory T cell flow cytometric assay . Samples also analyze presence VEGF , VEGFR , IFN-γ , IL-5 ELISA assay ; baseline expression Jak-STAT signaling intermediate ( Jak1 , Tyk2 , IFNAR , IRF9 ) immunoblot analysis ; interferon-stimulated gene expression real time PCR RT-PCR analysis . After completion study therapy , patient follow every 3 month 1 year , every 4 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Must histologically cytologically confirm clear cell renal cell carcinoma ( RCC ) Measurable disease , define ≥ 1 lesion accurately measure ≥ 1 dimension ≥ 1.0 cm spiral CT scan No prior treatment except PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy &gt; 6 month Good/intermediate Motzer prognostic status ANC ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10.0 g/dL Total bilirubin ≤ 2.0 mg/dL AST ALT &lt; 2.5 time normal Creatinine ≤ 1.8 mg/dL OR creatinine clearance &gt; 50 mL/min Calcium &lt; 12 mg/dL ( correct serum albumin ) INR &lt; 1.5 time upper limit normal Adequate cardiac function , define leave ventricular ejection fraction ≥ 40 % 2D echo Pulse oximetry ≥ 90 % rest room air Not pregnant Negative pregnancy test Fertile patient must use effective contraception No evidence bleed diathesis No uncontrolled coagulation disorder No active infection require IV antibiotic No known HIV , hepatitis C , hepatitis B No autoimmune disease require ongoing therapy No requirement adrenal replacement No angina ( control uncontrolled ) No uncontrolled hypertension No history major medical illness include , limited , follow : Cardiac ischemia Myocardial infarction Major cardiac arrhythmia Inflammatory bowel disorder No prior malignancy except previously treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree 3 year No significant psychiatric disease , opinion principal investigator , would preclude give adequate inform consent render immunotherapy unsafe PRIOR CONCURRENT THERAPY : No prior treatment RCC except sunitinib malate Patients may progress intolerant sunitinib malate No prior systemic treatment metastatic disease ( sunitinib malate ) No prior organ allograft At least 2 week since prior laparoscopic/robotic surgery At least 4 week since prior open nephrectomy More 4 week since prior concurrent radiotherapy surgery More 4 week since prior systemic steroid More 2 week since prior topical , injected , inhaled steroid No concurrent steroid therapy No concurrent Hypericum perforatum ( St. John 's wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>